Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

Acquired byBiotie Therapies
Price$122M
Date1/2011

General Information

Websitesynosia.com
CategoryBioTech
Emailjulie.walters@tud...
Employees
DescriptionPharmaceutical Compounds

Offices

Headquarters
Aeschenvorstadt 36
CH-4051
Basel, CHE

People

CEO & President
CFO
Board Observer

Funding

Tags

Synosia Therapeutics

Synosia Therapeutics develops and intends to commercialise products for unmet medical needs in psychiatry and neurology. The privately-owned company has in its pipeline six clinical-stage compounds acquired through partnerships with Novartis, Roche and Syngenta. Two of the compounds are marketed drugs being tested in new indications to extend their reach into neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson’s disease.

Recent Milestones

Videos

Screenshots

Sources

  1. Biotie buys CNS developer Synosia in $121.5M deal Read more: Biotie buys CNS developer Synosia in $121.5M deal - FierceBiotech http://www.fiercebiotech.com/story/biotie-buys-cns-developer-synosia-1215m-deal/2011-01-11?utm_medium=rss&utm_source=rss#ixzz1A (fiercebiotech.com) [edit]
  2. Neurological co. Synosis raises $32.5M (venturebeat.com) [edit]
  3. Synosia raises $29M for Phase II testing (fiercebiotech.com) [edit]
  4. Synosia Therapeutics Raises $30M in Series C Financing (synosia.com) [edit]
  5. UCB and Synosia Therapeutics sign strategic alliance in neurology (synosia.com) [edit]
Edit This Page
Last Edited 11/27/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy